---
title: "LeonaBio, Inc. (LONA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/LONA.US.md"
symbol: "LONA.US"
name: "LeonaBio, Inc."
industry: "制藥"
---

# LeonaBio, Inc. (LONA.US)

| Item | Detail |
|------|--------|
| Industry | 制藥 |
| Location | 美股市場 |
| Website | [leonabio.com](https://leonabio.com) |

## Company Profile

LeonaBio, Inc.是一家臨床階段的生物制藥公司，專注于開發小分子以恢复神經健康並減緩神經退行性變。其產品管線包括用于治療肌萎縮側索硬化症的 ATH-1105，目前處于第一階段臨床試驗；用于治療神經退行性疾病的 ATH-1020，也處于第一階段臨床試驗，以及處于臨床前階段的早期化合物。該公司之前名為 Athira Pharma, Inc.，並更名為 LeonaBio, Inc

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.39 | 114/257 | - | - | - |
| PB | 1.96 | 88/257 | 2.03 | 1.69 | 1.55 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-26T05:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 67% |
| Overweight | 0 | 0% |
| Hold | 1 | 33% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.34 |

## References

- [Company Overview](https://longbridge.com/en/quote/LONA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/LONA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/LONA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.